High Throughput Isolation and Data Independent Acquisition Mass Spectrometry (DIA-MS) of Urinary Extracellular Vesicles to Improve Prostate Cancer Diagnosis

Hao Zhang, Gui-Yuan Zhang, Wei-Chao Su, Ya-Ting Chen, Yu-Feng Liu, Dong Wei, Yan-Xi Zhang, Qiu-Yi Tang, Yu-Xiang Liu, Shi-Zhi Wang, Wen-Chao Li, Anke Wesselius, Maurice P. Zeegers, Zi-Yu Zhang, Yan-Hong Gu, W. Andy Tao*, Evan Yi-Wen Yu*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Proteomic profiling of extracellular vesicles (EVs) represents a promising approach for early detection and therapeutic monitoring of diseases such as cancer. The focus of this study was to apply robust EV isolation and subsequent data-independent acquisition mass spectrometry (DIA-MS) for urinary EV proteomics of prostate cancer and prostate inflammation patients. Urinary EVs were isolated by functionalized magnetic beads through chemical affinity on an automatic station, and EV proteins were analyzed by integrating three library-base analyses (Direct-DIA, GPF-DIA, and Fractionated DDA-base DIA) to improve the coverage and quantitation. We assessed the levels of urinary EV-associated proteins based on 40 samples consisting of 20 cases and 20 controls, where 18 EV proteins were identified to be differentiated in prostate cancer outcome, of which three (i.e., SERPINA3, LRG1, and SCGB3A1) were shown to be consistently upregulated. We also observed 6 out of the 18 (33%) EV proteins that had been developed as drug targets, while some of them showed protein-protein interactions. Moreover, the potential mechanistic pathways of 18 significantly different EV proteins were enriched in metabolic, immune, and inflammatory activities. These results showed consistency in an independent cohort with 20 participants. Using a random forest algorithm for classification assessment, including the identified EV proteins, we found that SERPINA3, LRG1, or SCGB3A1 add predictable value in addition to age, prostate size, body mass index (BMI), and prostate-specific antigen (PSA). In summary, the current study demonstrates a translational workflow to identify EV proteins as molecular markers to improve the clinical diagnosis of prostate cancer.

Original languageEnglish
Article number8155
Number of pages17
JournalMolecules
Volume27
Issue number23
DOIs
Publication statusPublished - 23 Nov 2022

Keywords

  • Male
  • Humans
  • Prostate
  • Proteomics/methods
  • Mass Spectrometry/methods
  • Extracellular Vesicles/metabolism
  • Prostatic Neoplasms/diagnosis

Cite this